Target intelligence / Profile preview

Fibrin matrix scaffold (None)

Target
None
Molecular classification
Other (biomaterial scaffold, extracellular matrix mimic)
01

Overview

The fibrin matrix scaffold is a naturally occurring or bioengineered network made primarily of cross-linked fibrin protein, formed from fibrinogen by thrombin during blood clotting. It provides a temporary, highly biocompatible and biodegradable extracellular matrix for cells. In tissue engineering, the scaffold allows for cell migration, adhesion, proliferation, and differentiation, facilitating the repair, regrowth, or substitution of damaged or defective tissues. Fibrin scaffolds can be modified with other biopolymers or chemically cross-linked to improve mechanical properties and degradation rates, and may be used as carriers for stem cells or therapeutic agents. They are broadly used in regenerative therapies for skin, nerve, bone, and organ tissue engineering and have vital roles in wound healing and hemostasis.

Other names
Fibrin scaffoldFibrin hydrogelFibrin glueFibrin sealant
02

Mechanism of action

Promotes cell migration and tissue ingrowth by providing a biocompatible, biodegradable scaffold Serves as a carrier for cells or bioactive molecules/drugs Controls release of factors (antibiotics, growth factors) loaded into the scaffold Can be modified to control degradation rates and mechanical stability

03

Biological functions

Cell migrationCell proliferationCell differentiationTissue regenerationHemostasis (blood clotting)Wound healingCell adhesion
04

Disease associations

Tissue damage repair (skin, bone, nerve injuries)Wound healingSurgical tissue repair (including bone, heart, eye, kidney, etc.)Other (used generally in regenerative medicine, not specific to a single disease)
05

Safety considerations

Rapid degradation rate can limit stability and support for regenerating tissueVariable fibrinolysis (breakdown) may compromise scaffold function unless modulatedMechanical integrity needs to match the tissue being regeneratedGenerally low toxicity; autologous (patient-derived) fibrin reduces immunogenic risk
06

Interacting drugs

tranexamic acid

1 more in the full profile.

07

Biomarkers

None directly; efficacy is measured by tissue regeneration markers (e.g., cell viability, new extracellular matrix, angiogenesis)

Beyond the preview

Go deeper on Fibrin matrix scaffold (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrin matrix scaffold (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call